HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic

by Emily E. Morin, Emily E. Morin, Xiang-An Li, Anna Schwendeman, Anna Schwendeman
Published 2018-11-01

HDL in sepsis - risk factor and therapeutic approach

by Emily E Morin, Ling eGuo, Anna eSchwendeman, Xiang-An eLi
Published 2015-10-01

Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice

by Emily E. Morin, Yanhong Guo, Hongliang He, Wenmin Yuan, Whitney N. Souery, Maria V. Fawaz, Yuqing Eugene Chen, Anna Schwendeman, Anna Schwendeman
Published 2020-12-01

Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization

by Jie Tang, Dan Li, Lindsey Drake, Wenmin Yuan, Sara Deschaine, Emily E. Morin, Rose Ackermann, Karl Olsen, David E. Smith, Anna Schwendeman
Published 2017-01-01

Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression

by Yanhong Guo, Wenmin Yuan, Bilian Yu, Rui Kuai, Wenting Hu, Emily E. Morin, Minerva T. Garcia-Barrio, Jifeng Zhang, James J. Moon, Anna Schwendeman, Y. Eugene Chen
Published 2018-02-01

The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties[S]

by Anna Schwendeman, Denis O. Sviridov, Wenmin Yuan, Yanhong Guo, Emily E. Morin, Yue Yuan, John Stonik, Lita Freeman, Alice Ossoli, Seth Thacker, Salena Killion, Milton Pryor, Y.Eugene Chen, Scott Turner, Alan T. Remaley
Published 2015-09-01

Synthetic high-density lipoprotein nanoparticles for the treatment of Niemann–Pick diseases

by Mark L. Schultz, Maria V. Fawaz, Ruth D. Azaria, Todd C. Hollon, Elaine A. Liu, Thaddeus J. Kunkel, Troy A. Halseth, Kelsey L. Krus, Ran Ming, Emily E. Morin, Hayley S. McLoughlin, David D. Bushart, Henry L. Paulson, Vikram G. Shakkottai, Daniel A. Orringer, Anna S. Schwendeman, Andrew P. Lieberman
Published 2019-11-01